Intraocular Pressure Immediately Following Intravitreous Injection of Ranibizumab

Completed

Conditions studied: Choroidal Neovascularization

In brief

This study will quantify the intraocular pressure elevation in the immediate time period following intravitreous injection. With more widespread use of intravitreous injections in patients that may require several injections per year, it is important to document the sudden increase in intraocular pressure, including the maximum intraocular pressure and the time required for the intraocular pressure to return to baseline. This data may be useful in stimulating additional studies to evaluate the long term ocular effects of repeated intravitreous injections. We hypothesize that the intraocular pressure increases significantly following intravitreous injection and then returns to baseline during the initial thirty minutes following ranibizumab injection.

Key facts

Study ID

NCT00417703

Run by

Oklahoma State University Center for Health Sciences

People needed

75

Starts

2007-01-01

Expected to finish

2008-01-01

Last updated by the study team

2008-01-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or Female Patients >18 years of age
• Patients will have documented choroidal neovascular membranes on fluorescein angiogram and/or optical coherence tomography
• Requiring treatment or maintenance therapy for choroidal neovascular membrane
• Able and willing to provide written informed consent

You may not qualify if…

• History of arterial occlusive disease of the eye.
• History of advanced glaucoma.

Where it is running

• Retina Support Services, Inc — Tulsa, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.